Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Open access

Abstract

Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies. The novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, effectively kills GPRC5D+ MM cell lines in the presence of T cells from both healthy donors or heavily pretreated MM patients. In addition, talquetamab has potent anti-MM activity in bone marrow (BM) samples from 45 patients, including those with high-risk cytogenetic aberrations. There was no difference in talquetamab-mediated killing of MM cells from newly diagnosed, daratumumab-naïve relapsed/refractory (median of 3 prior therapies), and daratumumab-refractory (median of 6 prior therapies) MM patients. Tumor cell lysis was accompanied by T-cell activation and degranulation, as well as production of pro-inflammatory cytokines. High levels of GPRC5D and high effector:target ratio were associated with improved talquetamab-mediated lysis of MM cells, whereas an increased proportion of T cells expressing PD-1 or HLA-DR, and elevated regulatory T-cell (Treg) counts were associated with suboptimal killing. In cell line experiments, addition of Tregs to effector cells decreased MM cell lysis. Direct contact with bone marrow stromal cells also impaired the efficacy of talquetamab. Combination therapy with daratumumab or pomalidomide enhanced talquetamab-mediated lysis of primary MM cells in an additive fashion. In conclusion, we show that the GPRC5D-targeting T-cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing studies with talquetamab in relapsed/refractory MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020003805

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 43 · Cited by 182

Metadata

Authors
Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., Sendecki, J., Wong, A., Verona, R. I., Sonneveld, P., Zweegman, S., Adams, H. C., Mutis, T., & van de Donk, N. W. C. J.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
  • Erasmus MC Cancer Institute (NL)
  • Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;
  • Institute of Cancer Research (GB)
  • NYU Langone Health (US)
  • Janssen Research & Development, Spring House, PA
Venue
Blood Advances
Published
2021-04-23
Volume
5
Issue
8
Pages
2196-2215
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3154427589
Cited by
182
References
43
Citations by year
2026: 29 · 2025: 41 · 2024: 58 · 2023: 33 · 2022: 16 · 2021: 5
FWCI
18.25
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Amgen
  • Sanofi
  • Celgene
  • SkylineDx
  • International Myeloma Society
  • Servier
  • Janssen Research and Development
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
talquetamab, GPRC5D, multiple myeloma, bispecific antibodies, G protein-coupled receptors, T cell cytotoxicity, regulatory T cells, PD-1, HLA-DR, mesenchymal stem cells, relapsed/refractory multiple myeloma, effector-to-target ratio, cytokine production
MeSH terms
Humans, Lymphocyte Activation, Multiple Myeloma, Antibodies, Bispecific, T-Lymphocytes, Regulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020003805
The paper
Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., Sendecki, J., Wong, A., Verona, R. I., Sonneveld, P., Zweegman, S., Adams, H. C., Mutis, T., & van de Donk, N. W. C. J. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020003805

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.